FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL							
OMB Number:	3235- 0104						
Estimated average burden							
hours per	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Cowen Aaron			Requiring S (Month/Day	2. Date of Event Requiring Statement (Month/Day/Year) 08/28/2024 3. Issuer Name and Ticker or Trading Symbol PROKIDNEY CORP. [PROK]							
(Last) C/O SUVRE MANAGEM 540 MADISO FLOOR	ENT, LLC				4. Relationship of Reporting Issuer (Check all applicable) Director Officer (give title below)	7 10% C) wner (specify	File 6. Iı	d (Month/Day/ ndividual or Jo eck Applicable Form filed I	int/Group Filing	
(Street) NEW YORK	NY	10022	_						- reison	oy More than One Person	
(City)	(State)	(Zip)									
Table I - Non-Derivative Securities Beneficially Owned											
1. Title of Security (Instr. 4)			E	. Amount of Securities Beneficially Owned (Instr.)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		4. Nature of Indirect Beneficial Ownership (Instr. 5)				
Class A ordinary shares, par value \$0.0001 per share				e	11,428,937(1)	I (5)		<u>I</u> (5)			
Class A ordinary shares, par value \$0.0001 per share				e	912,329(2)	I (5)		<u>I</u> (5)			
Class A ordinary shares, par value \$0.0001 per share				e	144,917 ⁽³⁾	I		I (3)			
Class A ordinary shares, par value \$0.0001 per share			e	712,583(4)	D						
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)											
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)		ate	3. Title and Amount of Securitie Underlying Derivative Security (Instr. 4)		4. Convers or Exerc Price of			6. Nature of Indirect Beneficial Ownership (Instr.			
			Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security		or Indirect (I) (Instr. 5)	5)	

Explanation of Responses:

- 1. Notes are included on Exhibit 99.1 hereto.
- 2. Notes are included on Exhibit 99.1 hereto.
- 3. Notes are included on Exhibit 99.1 hereto.
- 4. Notes are included on Exhibit 99.1 hereto.
- 5. Notes are included on Exhibit 99.1 hereto.

Remarks:

Exhibit List: Exhibit 99.1 - Explanation of Responses

/s/ Aaron Cowen

10/22/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Explanation of Responses:

- (1) Reflects Class A ordinary shares, par value \$0.0001 per share, of ProKidney Corp. (the "Class A ordinary shares") directly held by Averill Master Fund, Ltd. (the "Averill Fund").
- (2) Reflects Class A ordinary shares directly held by Averill Madison Master Fund, Ltd.. (the "Averill Madison Fund").
- (3) Reflects 144,917 Class A ordinary shares held by The Aaron Cowen 2012 Family Trust, which is for the benefit of certain immediate family members of Mr. Cowen and for which Mr. Cowen's spouse serves as the trustee.
 - (4) Reflects 712,583 Class A ordinary shares directly held by Mr. Cowen.
- (5) Mr. Cowen may be deemed to control Suvretta Capital Management, LLC, the investment manager of each of the Averill Fund and the Averill Madison Fund, and therefore may be deemed to beneficially own the Class A ordinary shares held by the Averill Fund and the Averill Madison Fund. Mr. Cowen disclaims beneficial ownership of the Class A ordinary shares reported herein except to the extent of any indirect pecuniary interest therein.